Objective To provide a comprehensive overview of the risk of venous thrombosis in women
using different combined oral contraceptives. Design Systematic review and network meta …

Background Combined oral contraceptive (COC) use has been associated with venous
thrombosis (VT)(ie, deep venous thrombosis and pulmonary embolism). The VT risk has …

Thrombophilia can be identified in about half of all patients presenting with venous
thrombosis. Testing has increased tremendously for various indications, but whether the …

Elevated plasma levels of factor VIII (> 150 IU/dL) are an important risk factor for deep vein
thrombosis (DVT). Factor VIII is the cofactor of factor IXa in the activation of factor X. The risk …

Venous thromboembolism (VTE), the third leading cause of cardiovascular mortality, is a
complex thrombotic disorder with environmental and genetic determinants. Although several …

There is now strong experimental evidence that tissue factor pathway inhibitor (TFPI) is a
critical inhibitor to modulate tissue factor–induced coagulation, but the role of TFPI as a risk …

Objective—To assess the risk of venous thrombosis associated with nonoral contraceptives
(ie, injectable depot–medroxyprogesterone acetate contraceptives, hormone …

Venous thromboembolism (VTE) is a significant contributor to morbidity and mortality. To
advance our understanding of the biology contributing to VTE, we conducted a genome …

Background Venous thrombosis is a common disease with a high mortality rate shortly after
the event. However, details on long-term mortality in these patients are lacking. The aim of …

Importance Little is known about the comparative cardiovascular safety of oral hormone
therapy products, which impedes women from making informed safety decisions about …